Veradigm (MDRX) Stock Overview
A healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MDRX from our risk checks.
MDRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Veradigm Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.70 |
| 52 Week High | US$11.80 |
| 52 Week Low | US$3.00 |
| Beta | 0 |
| 1 Month Change | 1.08% |
| 3 Month Change | 1.08% |
| 1 Year Change | -49.19% |
| 3 Year Change | -68.03% |
| 5 Year Change | -53.33% |
| Change since IPO | -13.60% |
Recent News & Updates
Recent updates
Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share Price
Feb 28
Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-Bagger
Nov 10Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher
Mar 06Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?
Feb 13Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 22These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well
Jan 04Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)
Dec 03Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%
Sep 28Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?
Sep 17Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist
Aug 24We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt
Jul 31Shareholder Returns
| MDRX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -1.1% | 2.7% | 2.0% |
| 1Y | -49.2% | 26.7% | 18.7% |
Return vs Industry: MDRX underperformed the US Healthcare Services industry which returned 26.3% over the past year.
Return vs Market: MDRX underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| MDRX volatility | |
|---|---|
| MDRX Average Weekly Movement | 5.9% |
| Healthcare Services Industry Average Movement | 8.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDRX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Don Trigg | veradigm.com |
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise.
Veradigm Inc. Fundamentals Summary
| MDRX fundamental statistics | |
|---|---|
| Market cap | US$806.69m |
| Earnings (TTM) | -US$20.04m |
| Revenue (TTM) | US$588.02m |
Is MDRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDRX income statement (TTM) | |
|---|---|
| Revenue | US$588.02m |
| Cost of Revenue | US$279.60m |
| Gross Profit | US$308.42m |
| Other Expenses | US$328.46m |
| Earnings | -US$20.04m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MDRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/27 11:19 |
| End of Day Share Price | 2025/10/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Veradigm Inc. is covered by 30 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Matthew Gillmor | Baird |
| Lawrence Marsh | Barclays |